MedPath

CS Diagnostics Enlists Lachman Consultants to Secure FDA Approval for Novel Cancer Treatment Hydrogel

• CS Diagnostics Corp. (OTCQB:CSDX) has appointed Lachman Consultants to navigate the FDA approval process for its innovative CS-Protect Hydrogel, an organ spacer technology for cancer radiotherapy treatments.

• The CS-Protect Hydrogel offers significant advantages over previous products, including enhanced versatility for multiple pathologies, ready-to-use application, and reduced contamination risks during cancer treatment procedures.

• The company anticipates FDA approval within 3-4 months and projects production to begin in Q1 2026, with executives noting that a predecessor technology was acquired by Boston Scientific for $500 million.

CS Diagnostics Corp. (OTCQB:CSDX) has appointed Lachman Consultants to lead regulatory efforts for FDA approval of its CS-Protect Hydrogel, an innovative tissue spacer technology designed to improve radiation treatments for cancer patients.
The Wyoming-based company announced the strategic partnership on March 12, highlighting Lachman Consultants' extensive experience in regulatory affairs and compliance services for pharmaceutical and medical device industries since 1978. The consultancy will provide specialized expertise to navigate the complex FDA approval process for the novel hydrogel technology.

Advanced Organ Protection Technology

CS-Protect Hydrogel functions as an organ spacer medical device that creates separation between critical organs and targeted tissue during radiation therapy. This separation helps minimize radiation exposure to healthy tissues while allowing for more precise treatment of cancerous areas.
According to company officials, the hydrogel represents a significant advancement over previous technologies in the field. "CS-Protect Hydrogel is more versatile and can be used in other pathologies beyond current applications," the company stated in its announcement. The product features advanced molecular structure and improved chemical and physical properties that enhance its medical applications.
The company anticipates a relatively swift approval timeline of 3-4 months for the U.S. market, following the completion of required testing procedures.

Clinical Advantages and Safety Features

Thomas Fahrhoefer, President of the Board at CS Diagnostics, emphasized the product's safety profile and ease of use: "The easy application of the CS-Protect Hydrogel being a ready-to-use product after removal from sterile packaging and unrequired further work steps eliminates any risk of contamination due to preparation and assembly."
This ready-to-use design removes potential hygienic risks within treatment rooms and eliminates concerns about improper mixing or preparation that could lead to missed treatments or suboptimal outcomes for patients undergoing radiation therapy.

Market Potential and Production Timeline

The company has positioned CS-Protect Hydrogel as a potentially valuable asset in the medical device market. Mohammad EsSayed, Vice President of the Board, noted that a predecessor product was acquired by Boston Scientific for $500 million, suggesting significant market potential for the new technology.
"We project the start of the production of CS-Protect Hydrogel in the U.S. market towards the first quarter of 2026," EsSayed stated, outlining the company's timeline following anticipated FDA approval.

Radiation Therapy Context

Radiation therapy remains a cornerstone of cancer treatment, with an estimated 50-60% of cancer patients receiving this therapy during their treatment course. Protecting healthy tissues during these procedures is critical for reducing side effects and improving patient outcomes.
Hydrogel spacers have emerged as important tools in radiation oncology, particularly for protecting organs adjacent to treatment sites. The technology has shown particular value in prostate cancer treatment, where hydrogel spacers can create separation between the prostate and rectum, reducing rectal toxicity during radiation therapy.

Corporate Strategy

As a publicly traded company on the OTCQB market, CS Diagnostics is positioning this product development as part of a broader strategy for growth. The company aims to provide U.S. investors with access to what it describes as a "high-growth opportunity" in the medical device sector.
The partnership with Lachman Consultants represents a significant step in the company's regulatory strategy. Lachman brings expertise in compliance, regulatory affairs, and technical services across pharmaceutical, biotechnology, biologics, cell and gene therapy, and medical device industries.
CS Diagnostics has indicated that further information about the CS-Protect Hydrogel technology is available on the company's website, with additional details expected as the approval process advances.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

CMS Grants ADLT Status to Guardant Health's Shield Blood Test for Colorectal Cancer Screening

The Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health's Shield blood test, the first FDA-approved blood test for primary colorectal cancer screening.
Beginning April 1, 2025, Medicare will reimburse the Shield test at $1,495 during the initial nine-month ADLT period, representing a significant increase from the previous $920 reimbursement rate.

Beckman Coulter's DxC 500i Clinical Analyzer Receives FDA Clearance, Enhancing Integrated Laboratory Testing Capabilities

Beckman Coulter's DxC 500i Clinical Analyzer has received FDA 510(k) clearance, offering integrated clinical chemistry and immunoassay testing with throughput of up to 800 chemistry and 100 immunoassay tests per hour.
The system features FlexMode operations that prioritize testing based on sample urgency, and a dynamic sample handler that manages repeats and re-runs without operator intervention, optimizing workflow efficiency.

Tempus Launches FDA-Approved xT CDx Test Nationwide for Comprehensive Solid Tumor Profiling

Tempus AI has commercially launched xT CDx, an FDA-approved 648-gene NGS-based diagnostic test for solid tumor profiling, offering comprehensive genomic insights across multiple cancer types.
The test serves as a companion diagnostic for identifying KRAS wild-type colorectal cancer patients suitable for cetuximab treatment and KRAS/NRAS wild-type patients for panitumumab therapy.

Sonoma Pharmaceuticals Gains FDA Clearance for Enhanced Microcyn Hydrogel

Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microcyn-based hydrogel, enhancing its wound care applications.
The new clearance includes improved biocompatibility and extends the product's shelf life to 24 months for 50mL bottles.

CytoSorbents Seeks Approval for DrugSorb-ATR in Canada to Reduce Bleeding in Heart Surgery

CytoSorbents has submitted a Medical Device License application to Health Canada for DrugSorb-ATR, targeting reduced bleeding during CABG surgery in patients on ticagrelor.
The application follows successful MDSAP certification, ensuring compliance with quality management system requirements in Canada and the U.S.

KSQ Therapeutics' CRISPR-Engineered TIL Therapy, KSQ-004EX, Receives FDA IND Clearance for Advanced Solid Tumors

KSQ Therapeutics received FDA clearance for its IND application for KSQ-004EX, a CRISPR/Cas9-engineered tumor-infiltrating lymphocyte (TIL) therapy.
KSQ-004EX targets advanced solid tumors by inactivating SOCS1 and Regnase-1 genes in TILs, enhancing anti-tumor potency and persistence.

FDA Accepts LEO Pharma's Delgocitinib Cream NDA for Chronic Hand Eczema

The FDA has accepted LEO Pharma's New Drug Application (NDA) for delgocitinib cream 2% for treating moderate to severe Chronic Hand Eczema (CHE) in adults.
The NDA is supported by Phase 3 DELTA 1 and DELTA 2 clinical trials, which demonstrated the efficacy and safety of delgocitinib cream compared to a cream vehicle.

FDA Grants Priority Review to Ionis' Olezarsen for Familial Chylomicronemia Syndrome

The FDA has accepted Ionis Pharmaceuticals' NDA for olezarsen with Priority Review for treating adults with familial chylomicronemia syndrome (FCS).
The FDA has set a target action date of December 19, 2024, for olezarsen and does not plan to hold an advisory committee meeting.

FDA Accepts Datopotamab Deruxtecan BLA for Nonsquamous NSCLC Treatment

The FDA has accepted the Biologics License Application (BLA) for datopotamab deruxtecan for treating advanced nonsquamous non-small cell lung cancer (NSCLC).
The BLA is based on the TROPION-Lung01 Phase III trial, which showed statistically significant improvement in progression-free survival (PFS) compared to docetaxel.

Concept Medical's MagicTouch Sirolimus-Coated Balloon Receives FDA IDE Approval for Small Vessel Coronary Disease

Concept Medical's MagicTouch SCB receives FDA IDE approval for treating small vessel coronary disease, marking the third IDE approval for the device family.
The approval allows Concept Medical to begin a pivotal clinical study to assess the safety and efficacy of MagicTouch SCB in small vessel coronary disease.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy